Pauline van der Meer Morh net worth and biography

Pauline van der Meer Morh Biography and Net Worth

Director of Viatris

Pauline van der Meer Mohr joined the Viatris board of directors after two years of service on the Mylan board, where she most recently was a member of the Compensation and Risk Oversight Committees. She also serves on the board of directors of HSBC Holdings, where she chairs the Group Remuneration Committee and is a member of the Group Audit, Group Risk and Nomination & Corporate Governance Committees. She is deputy chair of the supervisory board of Royal DSM N.V., chairs its Remuneration Committee and serves on its Nomination Committee; and is chair of the supervisory board of EY Netherlands LLP. Van der Meer Mohr also serves as the chair of the Dutch Corporate Governance Code Monitoring Committee and chair of the Appointment Advisory Committee for the President of the Supreme Court of the Netherlands, as well as being a member of the Capital Markets Committee of the AFM (the Dutch Authority for Financial Markets). She previously served on the supervisory board of ASML Holding N.V. and as president of the executive board of Erasmus University in Rotterdam. She has held several legal and management positions at Royal Dutch Shell Group and TNT N.V., was senior executive vice president and head of group human relations at ABN AMRO N.V., and served as a member of the Dutch Banking Code Monitoring Commission.

What is Pauline van der Meer Morh's net worth?: The estimated net worth of Pauline van der Meer Morh is at least $234,806.49 as of August 17th, 2022. Mr. van der Meer Morh owns 20,543 shares of Viatris stock worth more than $234,806 as of November 5th. This net worth estimate does not reflect any other assets that Mr. van der Meer Morh may own. Learn More about Pauline van der Meer Morh's net worth.
How do I contact Pauline van der Meer Morh?: The corporate mailing address for Mr. van der Meer Morh and other Viatris executives is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. Viatris can also be reached via phone at (724) 514-1800 and via email at [email protected]. Learn More on Pauline van der Meer Morh's contact information.
Has Pauline van der Meer Morh been buying or selling shares of Viatris?: Pauline van der Meer Morh has not been actively trading shares of Viatris during the past quarter. Most recently, Der Meer Mohr Pauline Van sold 9,440 shares of the business's stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $10.58, for a transaction totalling $99,875.20. Following the completion of the sale, the director now directly owns 20,543 shares of the company's stock, valued at $217,344.94. Learn More on Pauline van der Meer Morh's trading history.
Who are Viatris' active insiders?: Viatris' insider roster includes Paul Campbell (CAO and Corporate Controller), W. Cornwell (Director), Robert Coury (Chairman), Michael Goettler (CEO), James Kilts (Director), JoElleng Lyons Dillon (Director), Rajiv Malik (Director), Brian Roman (Chief Legal Officer), Menassie Taddese (insider), and Pauline van der Meer Morh (Director). Learn More on Viatris' active insiders.
Are insiders buying or selling shares of Viatris?: During the last twelve months, insiders at the sold shares 15 times. They sold a total of 940,050 shares worth more than $10,904,925.06. The most recent insider tranaction occured on September, 12th when Director Rajiv Malik sold 139,681 shares worth more than $1,628,680.46. Insiders at Viatris own 0.1% of the company. Learn More about insider trades at Viatris.
Information on this page was last updated on 9/12/2024.

Pauline van der Meer Morh Insider Trading History at Viatris

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/17/2022	Sell	9,440	$10.58	$99,875.20	20,543

Pauline van der Meer Morh Buying and Selling Activity at Viatris

Viatris Company Overview

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Today's Range

Now: $11.61

$11.33

$11.63

50 Day Range

MA: $11.60

$11.13

$12.08

2 Week Range

Now: $11.61

$8.95

$13.62

Volume

5,300,845 shs

Average Volume

8,546,397 shs

Market Capitalization

$13.86 billion

P/E Ratio

N/A

Dividend Yield

4.13%

Beta

0.93

Banking failure dead ahead

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.